LRRK2 詳細
Molecule Name
Leucine-rich repeat serine/threonine-protein kinase 2
分子の別称
PARK8,Leu-rich repeat,LRR-containing protein kinase 2,Dardarin
Drug Development Progress
治験薬の数11
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
PARK8，LRRK2，Leucine Rich Repeat Kinase 2，Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2，Parkinson Disease (Autosomal Dominant) 8，Augmented In Rheumatoid Arthritis 17，Dardarin，AURA17，RIPK7，ROCO2，Leucine-Rich Repeat Serine-Threonine Protein Kinase-2，DKFZp434H2111，FLJ45829
お問い合わせ
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| BIIB-094 | BIIB-094; ION-859; IONIS-BIIB7Rx | Phase 2 Clinical | Biogen Inc | Parkinson Disease | 詳細 |
| NEU-411 | NEU-411 | Phase 2 Clinical | Neuron23 Inc | Parkinsonian Disorders; Parkinson Disease | 詳細 |
| DNL-151 | BIIB122; DNL151; BIIB-122; DNL-151 | Phase 2 Clinical | Genentech Inc | Parkinson Disease | 詳細 |
| VRN-01 | VRN-01 | Phase 1 Clinical | Voronoi Inc | Glioblastoma | 詳細 |
| LRRK2 Kinase Inhibitors (Oncodesign/Servier) | ODS-2005294 | Phase 1 Clinical | Neoplasms; Parkinson Disease; Central Nervous System Diseases | 詳細 | |
| OPM-201 | OPM-201; S-221237 | Phase 1 Clinical | Oncodesign Biotechnology | Parkinson Disease | 詳細 |
| ARV-102 | ARV-102 | Phase 1 Clinical | Arvinas Inc | Supranuclear Palsy, Progressive; Parkinson Disease | 詳細 |
| HT-4253 | HT-4253 | Phase 1 Clinical | Halia Therapeutics Inc | Alzheimer Disease | 詳細 |
| FB418 | FB418 | Phase 1 Clinical | 1st Biotherapeutics Inc | Parkinsonian Disorders; Parkinson Disease; Amyotrophic Lateral Sclerosis | 詳細 |
| WXWH0226 | WXWH0226; WXWH-0226 | Phase 1 Clinical | Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd | Parkinson Disease | 詳細 |
| BT-0267 | BT 267; BT-0267 | Clinical | Brenig Therapeutics Inc | Parkinson Disease | 詳細 |